Participant flow12

How many started, completed or left each group, period by period.

1 to 12 of 12

Period	Milestone	Group	Participants
Overall Study	STARTED	Cetuximab	31
Overall Study	STARTED	Cetuximab and Carboplatin	71
Overall Study	Not Evaluable	Cetuximab	0
Overall Study	Not Evaluable	Cetuximab and Carboplatin	6
Overall Study	Early Progressors	Cetuximab	2
Overall Study	Early Progressors	Cetuximab and Carboplatin	5
Overall Study	Off Protocol	Cetuximab	5
Overall Study	Off Protocol	Cetuximab and Carboplatin	0
Overall Study	COMPLETED	Cetuximab	26
Overall Study	COMPLETED	Cetuximab and Carboplatin	60
Overall Study	NOT COMPLETED	Cetuximab	5
Overall Study	NOT COMPLETED	Cetuximab and Carboplatin	11

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT00232505/flow